Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)Toxicity From Sotorasib-Immunotherapy Combo Leads to New Approach

Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRAS
inhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led to
lower rates of grade 3-4 treatment-related adverse events compared with beginning
administration of the treatments concurrently.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form